Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multipotent and committed CD34+ cells in bone marrow transplantation.

H Ema1, T Suda, H Nakauchi

  • 1Department of Medicine, Jichi Medical School, Tochigi-ken.

Japanese Journal of Cancer Research : Gann
|May 1, 1991
PubMed
Summary

Hematopoietic stem cell transplantation (HSCT) recovery involves distinct CD34+ cell populations. CD34+, CD33+ cells act as committed progenitors, while CD34+, CD33- cells function as multipotent stem cells, showing different recovery patterns post-transplant.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diamond Blackfan anemia is mediated by hyperactive Nemo-like kinase.

Nature communications·2020
Same author

Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.

Leukemia·2017
Same author

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.

Blood cancer journal·2017
Same author

The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.

Blood cancer journal·2017
Same author

Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.

Leukemia·2016
Same author

Post-transplantation-emerging anti-HLA DQA1/DQB1 antibody possibly responsible for graft rejection after myeloablative-unrelated marrow grafting.

Bone marrow transplantation·2015

Area of Science:

  • Hematology
  • Immunology
  • Stem Cell Biology

Background:

  • Bone marrow transplantation (BMT) is crucial for treating hematological disorders.
  • Understanding the role of specific cell populations, like CD34+ cells, is vital for optimizing engraftment and recovery.
  • Hematopoietic recovery post-BMT is a complex process involving various progenitor and stem cell subsets.

Purpose of the Study:

  • To investigate the distinct roles of CD34+ cell subsets in hematological recovery after BMT.
  • To analyze the co-expression of CD34 and CD33 antigens on bone marrow cells during recovery.
  • To evaluate the in vitro hematopoietic function of CD34+ cells post-BMT.

Main Methods:

  • Analysis of bone marrow cells using fluorescence-activated cell sorting (FACS) with CD34 and CD33 antibodies.

Related Experiment Videos

  • Monitoring cell populations on days 14, 28, and later post-BMT in 6 recipients.
  • Performing single-cell cultures of CD34+ cells to assess hematopoietic progenitor function (colony-forming cells).

    • Main Results:

    • CD34+ cells were detectable by day 14 post-BMT.
    • Over 80% of CD34+ cells co-expressed CD33, with macrophage colony-forming cells predominating.
    • In normal marrow, CD34+, CD33+ cells comprised ~40% of CD34+ cells, with balanced erythroid, GM, and Mac colony formation.
    • After 10 weeks, CD34+, CD33- cells (multipotent stem cells) gradually recovered, correlating with peripheral blood recovery, showing increased erythroid burst-forming cells.

    Conclusions:

    • CD34+, CD33+ cells function as committed progenitors during early BMT recovery.
    • CD34+, CD33- cells represent multipotent stem cells with distinct biological behaviors and recovery kinetics.
    • These findings highlight the differential roles of CD34+ subsets in BMT hematological recovery.